October is #BreastCancerAwarenessMonth. #Celcuity joins individuals globally to honor those affected by breast cancer. Our team remains committed to clinically developing our lead drug candidate, gedatolisib, a potential first-in-class targeted therapy to treat breast cancer.

#News: Celcuity schedules the release of third quarter 2024 financial results for Thursday, November 14, 2024 at 4:30 PM ET: ir.celcuity.com/press-releases/ Live webcast presentation can be accessed here: viavid.webcasts.com/starthere.jsp?…

#News: This month Celcuity’s CEO and co-founder, Brian Sullivan, will participate in two fireside chats at the upcoming Stifel 2024 Healthcare Conference & the Jefferies London Healthcare Conference. Read the full press release here: ir.celcuity.com/press-releases/ #oncology

#News: Celcuity reports third quarter 2024 financials and provides recent updates: ir.celcuity.com/press-releases/ A live webcast/conference call at 4:30 p.m. ET today can be accessed using this weblink: viavid.webcasts.com/starthere.jsp?… #earnings #oncology #biotechnology

We expect 2025 to be a transformational year for Celcuity as we anticipate reporting several clinical data readouts throughout the year. Read more about our upcoming milestones in our fourth quarter earnings press release: ir.celcuity.com/press-releases/

We presented overall survival (OS) data at the SABCS 2024 from our Phase 1b study evaluating gedatolisib in combination with palbociclib and endocrine therapy. Read more here: ir.celcuity.com/press-releases/ View our poster from SABCS 2024 here: celcuity.com//wp-content/up…

#News: Celcuity schedules the release of first quarter 2025 financial results for Wednesday, May 14, 2025 at 4:30 PM ET: ir.celcuity.com/press-releases/ A live webcast presentation can be accessed using this link: viavid.webcasts.com/starthere.jsp?… #oncology #financialresults #earnings

#News: Celcuity reports first quarter 2025 financials and provides recent updates: ir.celcuity.com/press-releases/ A live webcast/conference call at 4:30 p.m. ET today can be accessed using this weblink: viavid.webcasts.com/starthere.jsp?… #earnings #financialresults #oncology

Celcuity reported early clinical data for geda: - Ph 1 (plus darolutamide in men w/ metastatic castration resistant prostate cancer): 6mo rPFS 66% - Ph 2 (plus trastuzumab-pkrb as 3L+ therapy in patients with HER2+ metastatic breast cancer): 43% ORR ir.celcuity.com/press-releases/

#News: Today, Celcuity announced issuance of a new patent for Gedatolisib that extends patent exclusivity into 2042 PR Here: ir.celcuity.com/press-releases/ #oncology #patent #biotechnology

#News: Today, Celcuity announced First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer PR Here: ir.celcuity.com/press-releases/ #teamcelcuity #oncology #biotechnology

#News: Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer on Monday, July 28, 2025, at 8:00 AM ET PR Here: ir.celcuity.com/press-releases/ #teamcelcuity #oncology #biotechnology

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Webcast: edge.media-server.com/mmc/p/uu6k4f9k/ PR: ir.celcuity.com/press-releases/ #teamcelcuity #oncology #biotechnology #data #phase3

#NEWS We’re excited to share positive topline data from our Phase 3 VIKTORIA-1 trial evaluating our lead candidate, a multi-target PI3K/AKT/mTOR inhibitor, as a treatment option for HR+/HER2- advanced breast cancer patients. Learn more here: bit.ly/4mjvMFW #meded #medex

From Reuters to Endpoints News, see the buzz around our positive Phase 3 topline data from the VIKTORIA-1 trial in advanced breast cancer. Learn more here: bit.ly/4mjvMFW #meded #medex

#NEWS: Celcuity schedules the release of second quarter 2025 financial results for Thursday, August 14, 2025 at 4:30 PM ET. A live webcast presentation can be accessed using this link: viavid.webcasts.com/starthere.jsp?… #teamcelcuity #financialresults #oncology #breastcancer #biotechnology